Dr. Maggie Scully is the Director of the Partnership Development Office at the Frederick National Laboratory for Cancer Research (FNLCR), the only national exclusively devoted to biomedical research. She supports the FNLCR’s mission to accelerate progress against cancer and AIDS by forging strategic partnerships between the lab’s scientists and external research communities, including government, academia, industry and nonprofit organizations. Previously, Dr. Scully was a scientist at the FNLCR’s Nanotechnology Characterization Lab. She spent over 9 years at the laboratory bench engineering and validating nanoparticles for drug delivery and imaging applications, predominantly for cancer indications. Dr. Scully co-founded a start-up company dedicated to the clinical translation of biopharmaceuticals for cancer, diabetes and rare disease indications. The company, which is based on licensed technology from Johns Hopkins University, is currently part of a large clinical-stage parent company. Dr. Scully completed a postdoctoral fellowship at Johns Hopkins Institute for NanoBioTechnology and Johns Hopkins School of Medicine’s Department of Radiology. As a doctoral student, she was in the NIH Intramural Research Program at the National Institute of Biomedical Imaging and Bioengineering. She received her Ph.D. in Biomedical Engineering from Stony Brook University and her B.S. in Bioengineering from Lehigh University.